TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03548064

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

Cause of deathStaffing, sites or logistics Automatic label, confidence 0.9, unverified. How labels are made.
“COVID 19 cases at the site”

The sponsor’s own words in the registry.

Life of this trial

201820192020202120222023Registered2018-05-24Started2019-03-10Stopped2020-12-31Results posted2022-01-18

Vital statistics

Status
Terminated
Phase
Phase 1
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor type
US National Institutes of Health
Conditions
Gastroenteritis Escherichia Coli; Immunisation
Interventions
Placebo; Placebo; Placebo; Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine; Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine; Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Participants
75
Sites
2
Countries
Bangladesh, United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.